BioTuesdays

Category - Feature

Feature

In conversation with Zoe Barry

As founder and CEO of ZappRx, a consumer engagement company focused on improving the electronic prescription process, Zoe Barry began her career as an analyst at hedge fund, Dawson Capital, in New York, where her role...

September 10, 2013
Feature

Stereotaxis sees Japanese reimbursement by year end

After receiving regulatory clearance in Japan of its Niobe Remote Magnetic Navigation system for cardiac ablations last March, Stereotaxis (NASDAQ:STXS) now expects to achieve reimbursement approval by the end of the...

September 3, 2013
Feature

In conversation with Rudy Mazzocchi

As president and CEO of closely-held ELENZA, Rudy Mazzocchi knows a thing or two about taking startups across the finish line. Among other things, he was the founder of eV3, which is now part of Covidien, and co-founder...

August 27, 2013
Feature

Galectin targets silent epidemic in liver fibrosis

Fatty liver disease, or the accumulation of fat in liver cells, is a “silent epidemic,” says Dr. Peter Traber, president, CEO and chief medical officer of Galectin Therapeutics (NASDAQ:GALT). In an interview with...

August 20, 2013
Feature

RedHill readying Phase 3 trials in Crohn’s

With a PDUFA target date of Feb. 3, 2014 for its migraine drug, RHB-103, and NDA filing planned for the first quarter of 2014 for the anti-emetic drug, RHB-102, RedHill Biopharma (NASDAQ,:RDHL; TASE:RDHL) is now...

August 13, 2013
Feature

Elite eyes home run in abuse-resistant technology

After reinventing itself in 2011, Elite Pharmaceuticals (OTCBB:ELTP) has bounced back with a line of generic drugs and is banking on the development of abuse-resistant opioids and once-daily opioid products to fuel its...

August 6, 2013
Feature

In conversation with Todd Wyche

As CEO and a co-founder of Brinson Patrick Securities, Todd Wyche has championed the use and growth of at-the-market offerings (ATMs) for the past 17 years for REITs, energy companies and most recently, biotech and life...

July 2, 2013
Feature

Avivagen shifts to commercial mindset from R&D

Cameron Groome, who moved into the executive suite at Avivagen (TSX-V:VIV) in March, has transformed the focus of the animal wellness company to a business and product development engine and away from an earlier...

June 18, 2013